Kevin Balthaser - Sep 1, 2023 Form 4 Insider Report for Aclaris Therapeutics, Inc. (ACRS)

Role: Chief Financial Officer
Signature: /s/ Mark Ballantyne, Attorney-in-Fact
Stock symbol: ACRS
Transactions as of: Sep 1, 2023
Transactions value $: -$2,252
Form type: 4
Date filed: 9/5/2023, 05:08 PM
Previous filing: Mar 3, 2023
Next filing: Sep 7, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ACRS	Common Stock	Options Exercise		+1K	+19.03%		6.26K	Sep 1, 2023	Direct	F1
transaction	ACRS	Common Stock	Tax liability	-$2.25K	-285	-4.56%	$7.90	5.97K	Sep 1, 2023	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ACRS	Restricted Stock Units	Options Exercise	$0	-1K	-50%	$0.00	1K	Sep 1, 2023	Common Stock	1K		Direct	F1, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.
F2	The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4.
F3	The shares underlying these restricted stock units vest over a period of two years, with one-half of the shares vesting on each of September 1, 2023 and September 1, 2024, subject to the reporting person's continuous service with the issuer as of the applicable vesting date.